Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of FGEN
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Volatile ride for FibroGen stock price on Monday moving between $1.02 and $1.17
(Updated on Apr 29, 2024)

Sell candidate since Apr 03, 2024 Loss -25.85% PDF

The FibroGen stock price gained 4.81% on the last trading day (Monday, 29th Apr 2024), rising from $1.04 to $1.09. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 14.71% from a day low at $1.02 to a day high of $1.17. The price has fallen in 7 of the last 10 days and is down by -16.79% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 518 thousand more shares were traded than the day before. In total, 1 million shares were bought and sold for approximately $1.27 million.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $0.94 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -33.43% during the next 3 months and, with a 90% probability hold a price between $0.625 and $1.26 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

FGEN Signals & Forecast

A buy signal was issued from a pivot bottom point on Wednesday, April 24, 2024, and so far it has risen 10.74%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). FibroGen has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The FibroGen stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $1.73. On a fall, the stock will find some support from the short-term average at $1.07. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

Support, Risk & Stop-loss for FibroGen stock

FibroGen finds support from accumulated volume at $1.07 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.150 between high and low, or 14.71%. For the last week, the stock has had daily average volatility of 14.96%.

FibroGen is oversold on RSI14 (18). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (FGEN) For The Upcoming Trading Day Of Tuesday 30th

For the upcoming trading day on Tuesday, 30th we expect FibroGen to open at $1.09, and during the day (based on 14 day Average True Range), to move between $0.90 and $1.28, which gives a possible trading interval of +/-$0.193 (+/-17.71%) up or down from last closing price. If FibroGen takes out the full calculated possible swing range there will be an estimated 35.43% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $1.07 (1.83%) than the resistance at $1.15 (5.50%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is FibroGen stock A Buy?

FibroGen holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -3.697 Sell Candidate Unchanged

Predicted Opening Price for FibroGen of Tuesday, April 30, 2024

Fair opening price April 30, 2024 Current price
$1.09 ( 0.306%) $1.09

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for FGEN

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.24 14.07 %
R2 1.19 8.81 %
R1 1.15 5.56 %
Current price: 1.09
Support S1 1.04 -4.95 %
S2 1.00 -8.20 %
S3 0.94 -13.46 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 1.30 19.27 %
R2 1.17 7.34 %
R1 1.15 5.50 %
Current price 1.09
Support S1 1.07 -1.83%
S2 1.02 -6.42%
S3 0.98 -9.70%

FAQ

What is the symbol for FibroGen Stock and on which exchange is it traded?
The symbol for FibroGen is FGEN and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell FibroGen Stock?
FibroGen holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy FibroGen Stock?
FibroGen Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy FibroGen Stock.

What's the current price of FibroGen Stock?
As of the end of day on the Apr 29, 2024, the price of an FibroGen (FGEN) share was $1.09.

What is the 52-week high and low for FibroGen Stock?
The 52-week high for FibroGen Stock is $19.47 and the 52-week low is $0.335.

What is the market capitalization of FibroGen Stock?
As of the Apr 29, 2024, the market capitalization of FibroGen is 108.427M.

When is the next earnings date for FibroGen?
The upcoming earnings date for FibroGen is May 13, 2024.
Click to get the best stock tips daily for free!

About FibroGen

FibroGen FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China ... FGEN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT